

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Withdrawn and Currently Amended) A process for the preparation of isotonic oil emulsions containing estrogen and progestagen for intravenous administration, comprising the steps of:
  - (A) providing at least one of estrogens and progestagens;  
providing an oil phase and an aqueous phase;  
providing an antioxidant;  
dissolving the at least one of the hormones-estrogen and progestagen in [[an]]the oil phase; and
  - (B) emulsifying the oil phase in the aqueous phase; in the presence of an emulsifier.
2. (Currently Amended) A hormone-containing isotonic oil emulsion for intravenous administration comprising:  
at least one of progestagens and estrogens[[.]];  
an oil phase;  
an antioxidant;  
an emulsifier; and  
an aqueous phase;  
wherein the at least one of the progestagens and estrogens are dissolved in the oil phase prior to being mixed with the aqueous phase obtainable by the process according to claim 1.
3. (Original) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2, comprising progestagens and estrogens in a ratio of from

2:1 to 200:1.

4. (Currently Amended) The oil emulsion according to claim 2-~~or~~3, characterized in that the emulsion contains from [[1]]0.005 to [[60]]0.5 by weight of an estrogen and from [[1]]0.05 to [[50]]5 by weight of a progestagen, based on the total composition.

5. (Currently Amended) The oil emulsion according to ~~any of claim[[s]] 2-to-4~~, characterized in that said estrogen is estradiol and said progestagen is progesterone.

6. (Currently Amended) The oil emulsion according to ~~any of claim[[s]] 2-to-5~~, characterized in that said oil phase comprises medium chain triglycerides (MCT) having a chain length of from 6 to 12, preferably from 8 to 10, carbon atoms.

7. (Currently Amended) The oil emulsion according to ~~any of claim[[s]] 2-to-6~~, characterized by containing up to 1.5% by weight of the emulsifier, based on the total composition.

8. (Withdrawn) Use of the isotonic oil emulsion according to any of claims 2 to 7 for preparing a medicament for intravenous administration of estrogen and progestagen for postnatal hormone substitution in premature babies.

9. (Withdrawn) Use of the isotonic oil emulsion according to any of claims 2 to 7 for preparing a medicament for the treatment of neurological damage after strokes.

10. (Withdrawn) A process for hormone substitution in premature babies by using the isotonic oil emulsion according to any of claims 2 to 7.

11. (Withdrawn) A process for the treatment of neurological damage after strokes by

**Appln No. 10/561,631**  
**Amdt date June 16, 2010**  
**Reply to Office action of March 3, 2010**

using the isotonic oil emulsion according to any of claims 2 to 7.

12. (New) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2; further comprising a co-emulsifier.

13. (New) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 12, wherein the co-emulsifier is present in an amount of from 0.005 to 0.1% by weight, based on the total composition.

14. (New) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2; wherein the antioxidant comprises tocopherols or tocopherol esters.

15. (New) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2; wherein the antioxidant is present in an amount from about 10mg to 1000mg, based on 100g of the oil phase.

16. (New) The hormone-containing isotonic oil emulsion for intravenous administration according to claim 2; having a pH value from 6.0 to 9.0.